<MedlineCitation Status="Completed">
<MedlineID>10011456</MedlineID>
<PMID>570422</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-3002</ISSN>
<JournalIssue>
<Volume>566</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Negative homotropic cooperativity in rat muscle AMP deaminase. A kinetic study on the inhibition of the enzyme by ATP.</ArticleTitle>
<Pagination>
<MedlinePgn>353-61</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>1. Rat skeletal muscle AMP deaminase (AMP aminohydrolase, EC 3.5.4.6) at optimal KCl concentrations shows a biphasic response to increasing levels of the allosteric inhibitor ATP. 2. Up to 10 micrometer, ATP appears to convert the enzyme to a form exhibiting sigmoidal kinetics while at higher concentrations its inhibitory effect is manifested by an alteration of AMP binding to AMP deaminase indicative of negative homotropic cooperativity at about 50% saturation. 3. AMP deaminase is inactivated by incubation with the periodate oxidation product of ATP. The (oxidized ATP)--AMP deaminase complex stabilized by NaBH4 reduction shows kinetic properties similar to those of the native enzyme in the presence of high ATP concentrations. 4. A plausible explanation of the observed cooperativity is that ATP induces different conformational state of AMP deaminase subunits, causing the substrate to follow a sequential mechanism of binding to enzyme. 5. Binding of the radioactive oxidized ATP shows that 3.2 mol of this reagent bind per mol AMP deaminase.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Raggi</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Ranieri-Raggi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>Biochim Biophys Acta</MedlineTA>
<NlmUniqueID>0217513</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Macromolecular Systems</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>56-65-5</RegistryNumber>
<NameOfSubstance>Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7447-40-7</RegistryNumber>
<NameOfSubstance>Potassium Chloride</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.4</RegistryNumber>
<NameOfSubstance>Nucleotide Deaminases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.5.4.6</RegistryNumber>
<NameOfSubstance>AMP Deaminase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>AMP Deaminase</DescriptorName>
<QualifierName MajorTopicYN="Y">antagonists &#38; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adenosine Triphosphate</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Macromolecular Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Muscles</DescriptorName>
<QualifierName MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Nucleotide Deaminases</DescriptorName>
<QualifierName MajorTopicYN="Y">antagonists &#38; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Oxidation-Reduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Potassium Chloride</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Protein Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Rats</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
